Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...
Of all the cephalosporins, only first-generation drugs should be considered for the treatment of GAS pharyngitis. The clearest advantage of cephalosporins is for patients in whom eradication of ...
TAXIS Pharmaceuticals is developing first-in-class anti-resistance drugs to help re-engage widely ... study of low-dose TXA709 with the generic cephalosporin antibiotic cefdinir is scheduled ...